While GDF15 levels can still be used to effectively distinguish CMT from GNE myopathy (Fig. 7D), there was a significant elevation of GDF15 within the GNE myopathy cohort compared to controls (Fig. 7A). This evidence concerns the gene GDF15 and GNE myopathy.